Cancer
Malignant Pancreatic Neoplasm
CI-CAN-00001159Explore in graph →
Top-level904 active trials8 approved drugs63 evidence items
- NCIt
- C9005
- ICD-10
- C25
- DOID
- 1793
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001159Explore in graph →
Clinical trials
3,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (516)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02718859 | Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02894944 | Clinical Trial Phase I for Theragene in Combination With Chemotherapy for the Locally Advanced Pancreatic Cancer(Theragene) | completed | Phase 1 | 9 | Seoul National University HospitalOTHER | 1 | Sep 12, 2019 |
| clinicaltrials |
| NCT03008304 | High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic Cancer | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02583477 | Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma | completed | Phase 1 / Phase 2 | 23 | AstraZenecaINDUSTRY | 2 | Aug 14, 2019 | clinicaltrials |
| NCT02734160 | A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer | completed | Phase 1 | 37 | Eli Lilly and CompanyINDUSTRY | 5 | Aug 5, 2019 | clinicaltrials |
| NCT01858883 | Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 55 | Incyte CorporationINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT02973672 | Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas | completed | Phase 1 / Phase 2 | 75 | SurgimabINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT02283372 | Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer | completed | Phase 1 | 30 | Washington University School of MedicineOTHER | 1 | Jun 19, 2019 | clinicaltrials |
| NCT01893801 | Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA | completed | Phase 1 / Phase 2 | 25 | Pancreatic Cancer Research TeamOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT01128296 | Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas | completed | Phase 1 / Phase 2 | 35 | Amer ZureikatOTHER | 1 | May 1, 2019 | clinicaltrials |
| NCT00923299 | Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine(THERAPY) | completed | Phase 1 / Phase 2 | 33 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01537107 | Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 31 | Mayo ClinicOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT01984658 | A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of ALECSAT to Pancreas Cancer Patients | completed | Phase 1 | 10 | CytoVac A/SINDUSTRY | 1 | Feb 26, 2019 | clinicaltrials |
| NCT00438256 | Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01286987 | Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | completed | Phase 1 | 113 | PfizerINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT02403271 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 124 | Pharmacyclics LLC.INDUSTRY | 1 | Jan 3, 2019 | clinicaltrials |
| NCT01839981 | CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 1 | 10 | Wake Forest University Health SciencesOTHER | 1 | Dec 27, 2018 | clinicaltrials |
| NCT01770132 | Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer | completed | Phase 1 | 12 | John DeWittOTHER | 1 | Dec 13, 2018 | clinicaltrials |
| NCT01453153 | Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer | completed | Phase 1 / Phase 2 | 28 | Halozyme TherapeuticsINDUSTRY | 2 | Nov 30, 2018 | clinicaltrials |
| NCT02960594 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse(TRT-001) | completed | Phase 1 | 93 | Inovio PharmaceuticalsINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT01833546 | A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer | completed | Phase 1 | 20 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Oct 15, 2018 | clinicaltrials |
| NCT02045589 | A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer | completed | Phase 1 | 8 | Theriva Biologics SLINDUSTRY | 1 | Oct 1, 2018 | clinicaltrials |
| NCT01663272 | A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer | completed | Phase 1 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT02620423 | Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | completed | Phase 1 | 11 | Oncolytics BiotechINDUSTRY | 1 | Sep 13, 2018 | clinicaltrials |
| NCT02191761 | Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer | completed | Phase 1 | 13 | Biosplice Therapeutics, Inc.INDUSTRY | 1 | Sep 7, 2018 | clinicaltrials |
| NCT01456585 | Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma | completed | Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 27, 2018 | clinicaltrials |
| NCT02166255 | APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 17 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT00892736 | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy | completed | Phase 1 | 98 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2018 | clinicaltrials |
| NCT01364805 | New Treatment Option for Pancreatic Cancer | completed | Phase 1 | 14 | Jeanne Drisko, MD, CNS, FACNOTHER | 1 | Jun 19, 2018 | clinicaltrials |
| NCT00600002 | Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma | completed | Phase 1 | 30 | Edward NelsonOTHER | 1 | Jun 11, 2018 | clinicaltrials |
| NCT00565487 | Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer | completed | Phase 1 | 15 | Milton S. Hershey Medical CenterOTHER | 1 | May 21, 2018 | clinicaltrials |
| NCT01373164 | A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 170 | Eli Lilly and CompanyINDUSTRY | 6 | May 16, 2018 | clinicaltrials |
| NCT02657330 | Study of SBP-101 in Pancreatic Cancer | completed | Phase 1 | 29 | Panbela Therapeutics, Inc.INDUSTRY | 2 | Apr 20, 2018 | clinicaltrials |
| NCT01342224 | Immunochemoradiotherapy in Patients With Pancreatic Cancer | completed | Phase 1 | 11 | Providence Health & ServicesOTHER | 1 | Apr 12, 2018 | clinicaltrials |
| NCT01843725 | Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers(MOMENTUM1) | completed | Phase 1 | 37 | Jules Bordet InstituteOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT01781520 | Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 47 | Capital Medical UniversityOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT00033241 | Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors | completed | Phase 1 | — | OSI PharmaceuticalsINDUSTRY | 1 | Jan 10, 2018 | clinicaltrials |
| NCT00622674 | Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 37 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00620295 | Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors | completed | Phase 1 | 17 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00703638 | Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00667082 | NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma | completed | Phase 1 | 22 | CelgeneINDUSTRY | 1 | Nov 22, 2017 | clinicaltrials |
| NCT02272738 | A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer | completed | Phase 1 | 54 | Osaka Medical Center for Cancer and Cardiovascular DiseasesOTHER | 1 | Nov 21, 2017 | clinicaltrials |
| NCT01897415 | Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer | completed | Phase 1 | 16 | University of PennsylvaniaOTHER | 1 | Sep 19, 2017 | clinicaltrials |
| NCT01730222 | A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma(PACT-19) | completed | Phase 1 / Phase 2 | 137 | IRCCS San RaffaeleOTHER | 1 | Sep 1, 2017 | clinicaltrials |
| NCT01783171 | Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 2 | Aug 22, 2017 | clinicaltrials |
| NCT00288093 | 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2017 | clinicaltrials |
| NCT01764477 | Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma | completed | Phase 1 | 20 | Prism Pharma Co., Ltd.INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT01383538 | FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma | completed | Phase 1 | 15 | Andrew KoOTHER | 1 | Aug 8, 2017 | clinicaltrials |
| NCT01040000 | QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer | completed | Phase 1 / Phase 2 | 94 | Precision Biologics, IncINDUSTRY | 1 | Aug 4, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Sep 12, 2019source: clinicaltrials